Evidence map›Paper›PMID 25535895›Full record

ArticleCancer biology & therapy2014

A breast cancer cell microarray (CMA) as a rapid method to characterize candidate biomarkers.

Xinyan Wu, Muhammad S Zahari, Santosh Renuse, Harrys K C Jacob, Sruthi Sakamuri, Mukul Singal, Edward Gabrielson, Saraswati Sukumar, Akhilesh Pandey

Abstract read
In one paragraph

Article in Cancer biology & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Living Cell Microarrays: An Overview of Concepts.Microarrays (Basel, Switzerland) · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xinyan Wua McKusick-Nathans Institute of Genetic Medicine and Department of Biological Chemistry ; Johns Hopkins University School of Medicine ; Baltimore , MD USA.
Muhammad S Zahari
Santosh Renuse
Harrys K C Jacob
Sruthi Sakamuri
Mukul Singal
Edward Gabrielson
Saraswati Sukumar
Akhilesh Pandey

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
Proteome Characterization Center: A Genoproteomics Pipeline for Cance ResearchU24CA160036 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI, ZHANG, HUI · 2011 to 2016
$10.7M
Networks, Pathways and Dynamics of Lysine ModificationU54GM103520 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI BADER, JOEL S. · 2012 to 2013
$7.0M
NCI NIH HHS BC051652NCI NIH HHS CA62924NCI NIH HHS P50 CA062924NCI NIH HHS U24 CA160036NCI NIH HHS U24CA160036NIGMS NIH HHS U54 GM103520NIGMS NIH HHS U54GM103520
6 · The paper itself

Abstract

Tissue microarrays (TMAs) have become an invaluable tool in cancer research to evaluate expression and subcellular localization of proteins in cells and tissues. As the catalogs of candidate biomarkers and therapeutic targets become more extensive, there is a need to characterize and validate these targets and biomarkers in cell lines as a primary biological system in research laboratories. Thus, cell microarrays (CMAs) are useful as a high-throughput screening tool. Here, we constructed a CMA containing 32 publicly available immortalized breast cell lines with the goal of creating a method to rapidly screen for antigens of interest in breast cancer research in a relatively easy, rapid and cost-effective manner. As proof of concept, we performed immunocytochemical staining of the HER2 receptor, as the status of this protein is relevant to breast cancer and has previously been reported for these cell lines. We observed a complete concordance of our staining with the published status of HER2 in these cell lines. In addition, we examined the expression of CD44, epithelial markers EpCAM and E-cadherin and tyrosine phosphoproteins. The labeling of these proteins correlates with the known biology of the cell lines. Our results demonstrate the utility of our method to screen for potential biomarkers and therapeutic targets in breast cancer and we suggest that CMAs be used as a general approach in breast cancer research.

Indexed as

Tissue Array AnalysisAntigens, NeoplasmBiomarkers, TumorBreast NeoplasmsCadherinsCell Adhesion MoleculesCell Line, TumorEpithelial Cell Adhesion MoleculeErb-b2 Receptor Tyrosine KinasesFemaleHumansHyaluronan ReceptorsImmunohistochemistryPhosphoproteinsAntigens, NeoplasmBiomarkers, TumorCadherinsCell Adhesion MoleculesEpithelial Cell Adhesion MoleculeErb-b2 Receptor Tyrosine KinasesHyaluronan ReceptorsPhosphoproteinsbiomarkerbreast cancerCD44cell microarrayCMA, cell microarrayE-cadherinEpCAMER, estrogen receptorHER2ICC, immunocytochemical stainingIHC, immunohistochemical stainingimmunocytochemical stainingphosphorylationPR, progesterone receptorTMA, tissue microarrayTNBC, triple negative breast cancer

Identifiers

PMID25535895
PMCPMC4622654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.